A Prospective Cohort of Children With HIV Infection (NCT00476606) | Clinical Trial Compass
CompletedNot Applicable
A Prospective Cohort of Children With HIV Infection
Thailand500 participantsStarted 2003-03
Plain-language summary
To evaluate clinical and immunological outcome of children treated with HAART.
Who can participate
Age range
1 Day – 20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center
* Children who fulfil criteria to start HAART according to the ATC program
* Children who are switched to second regimen or salvage therapy
* Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)
* Children with HIV infection who are not on antiretroviral therapy
* Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form
Exclusion Criteria:
* Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is an observational cohort study rather than a treatment trial, what does that mean for my child — will they receive any specific experimental treatment, or is this mainly about tracking their health and outcomes over time?
2This study focused on collecting data about children on HAART (combination antiretroviral therapy) — is HAART still the standard of care for my child, and how do the findings from a study like this shape the treatment approach you'd recommend today?
3The study is listed as completed — does that mean the data has been published or shared, and is there anything from its findings about clinical or immune outcomes in HIV-positive children that you think is relevant to my child's situation?
4Since this trial aimed to provide 'the best possible care' as part of its goals, how does that compare to what my child would receive through standard care outside of a research setting, and is there a meaningful difference?
5Are there currently any active studies or updated cohort programs for children with HIV that you'd recommend we look into, now that this particular study has finished enrolling?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection
Timeframe: every 3 months
Trial details
NCT IDNCT00476606
SponsorThe HIV Netherlands Australia Thailand Research Collaboration